IDIA Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.…
Industry Peers
BiotechnologyKey Statistics
About Idorsia (SWX: IDIA)
›
Idorsia (SWX: IDIA) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 424 employees.
The shares were at 3.746 CHF on 19 November 2026, up 19.1% over 52 weeks. Its 52-week range is 2.795 CHF to 7.560 CHF: the price is 50.4% below the high and 34.0% above the low.
Its market capitalisation is 1.01B CHF.
Idorsia reports return on equity of 9.8%, an operating margin of -68.4% and revenue up 49.3% year over year.
Its debt exceeds its cash by 1.24B CHF. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 5.000 CHF is 33.5% above the current price. The next earnings report is expected on 25 February 2027.